| Name | Title | Contact Details |
|---|
A.T. Works is a San Francisco, CA-based company in the Computers and Electronics sector.
Brite Semiconductor is a world-leading ASIC design services company, providing customers with ULSI ASIC/SoC chip design and manufacturing services. Brite Semiconductor was co-founded by Semiconductor Manufacturing International Corporation and Open-Silicon, as well as venture capital firms from China and abroad.
CLKDA is the market and technology leader in High Accuracy Timing and Variance Characterization. Our customers include the top global semiconductor companies. Our FX Applications solve mission critical problems for chip frequency, yield, and time to market. FX is the first transistor model and simulator specifically engineered for digital variance and delay analysis. FX is in production at the most advanced IC geometries at 20nm, 16nm, 14nm and 10nm, with all of the leading foundries. Variance FX is the leading solution for generating derates in the market today. Path FX is the only solution that delivers MC SPICE accuracy with better performance than even traditional STA tools. CLKDA was founded in 2005. Its management team has over 200 years of experience in EDA between them. Our headquarters is in Littleton, Massachusetts, just outside of Boston. CLKDA has offices in California, Texas and Taiwan.
Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.